SCHEMBL6179637

SCHEMBL6179637

CCc1nc(-c2ccccc2)cn1-c1ccc(CCO[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
AGER Q15109 4/20 0.35
FAAH O00519 1/20 0.34
TP53 P04637 3/20 0.34
RECQL P46063 2/20 0.34
PKM P14618 1/20 0.34
ALOX15 P16050 1/20 0.34
PTGS2 P35354 1/20 0.34
HSD11B1 P28845 1/20 0.33
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
PDE10A Q9Y233 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6253206 0.91 AGER (0.46) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6174783 0.89 PTGS2 (0.44) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6179907 0.89 LMNA (0.36) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6176741 0.87 GPR119 (0.41) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6329377 0.87 SMN1; SMN2 (0.38) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6175993 0.79 PTGS2 (0.41) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6179004 0.79 AGER (0.42) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6177327 0.79 SPNS2 (0.43) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL6178027 0.76 NPC1 (0.50) NPC1RAB9AGSK3B
SCHEMBL4447659 0.76 MAPT (0.41) SMN1; SMN2NPC1RAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6956050-B2 Imidazole compounds as anti-inflammatory and analgesic agents PFIZER, INC. (US) 2005-10-18 US disclosed
EP-1494667-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents HIRANO MISATO (JP) 2003-11-27 US disclosed
WO-2003086390-A1 IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220372-A1 Imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, PTGES SMN1; SMN2 4565/4885NPC1 959/4885RAB9A 1568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.